 "Anuh Pharma zooms over 25% in two days post bonus issue")
Shares of Anuh Pharma have rallied by 7% to Rs 352, extending their previous day’s over 15% surge on the BSE, after the stock turned ex-bonus on Wednesday, August 5, 2015.
The bulk drug manufacturer has fixed August 06, 2015 as the record date for the purpose of issuing bonus shares in the ratio of 2:1 i.e. two equity shares of face value of Rs 5 each for every one equity share of face value of Rs 5 each.
The stock touched a record high of Rs 356 in intra-day trades today, zooming by 26% in the past two trading sessions from Rs 282 (adjusted to bonus issue) on August 4.
Anuh Pharma is a debt-free company with revenues growing at a compound annual growth rate (CAGR) of 10% over the past 5 years.
The company said that it expects to significantly increase its market share on corticosteroids as well in the next couple of years, given the low base.
“The company’s immediate focus shall be on exploiting the current product approvals in Europe which offer a US $15 million opportunity; more approvals are pending which will enhance this addressable market further,” Anuh Pharma said in a investor presentation.
The three new products proposed for FY16 launch are in anti-bacterial and respiratory segments, Anuh Pharma added.
The bulk drug manufacturer has fixed August 06, 2015 as the record date for the purpose of issuing bonus shares in the ratio of 2:1 i.e. two equity shares of face value of Rs 5 each for every one equity share of face value of Rs 5 each.
The stock touched a record high of Rs 356 in intra-day trades today, zooming by 26% in the past two trading sessions from Rs 282 (adjusted to bonus issue) on August 4.
Anuh Pharma is a debt-free company with revenues growing at a compound annual growth rate (CAGR) of 10% over the past 5 years.
The company said that it expects to significantly increase its market share on corticosteroids as well in the next couple of years, given the low base.
“The company’s immediate focus shall be on exploiting the current product approvals in Europe which offer a US $15 million opportunity; more approvals are pending which will enhance this addressable market further,” Anuh Pharma said in a investor presentation.
The three new products proposed for FY16 launch are in anti-bacterial and respiratory segments, Anuh Pharma added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%